Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma

被引:21
作者
Jie, Yamin [1 ]
Liu, Guijun [2 ]
Mingyan, E. [3 ]
Li, Ying [4 ]
Xu, Guo [1 ]
Guo, Jingjing [5 ]
Li, Yinyin [6 ]
Rong, Guanghua [7 ]
Li, Yongwu [8 ]
Gu, Anxin [3 ]
机构
[1] Harbin Med Univ, Dept Radiat Oncol, Affiliated Hosp 4, Harbin 150001, Heilongjiang, Peoples R China
[2] Heilongjiang Univ Chinese Med Harbin, Affiliated Hosp 2, Harbin 150040, Heilongjiang, Peoples R China
[3] Harbin Med Univ, Canc Hosp, Dept Radiat Oncol, Harbin 150040, Heilongjiang, Peoples R China
[4] Harbin Med Univ, Inst Hard Tissue Dev & Regenerat, Affiliated Hosp 2, Harbin 150001, Heilongjiang, Peoples R China
[5] Chinese Peoples Liberat Army Gen Hosp, Dept Out Patient Clin, Med Ctr 1, Beijing 100853, Peoples R China
[6] Peoples Liberat Army Gen Hosp, Dept Liver Dis, Med Ctr 5, Beijing 100039, Peoples R China
[7] Peoples Liberat Army Gen Hosp, Dept Oncol, Med Ctr 5, Beijing 100039, Peoples R China
[8] Peoples Liberat Army Gen Hosp, Dept Radiol, Med Ctr 5, Beijing 100039, Peoples R China
关键词
Hepatocellular carcinoma; E26 transformation specific sequence 1; Small molecular inhibitor; Matrix metalloproteinase; SORAFENIB; CELLS; SENSITIVITY; ACTIVATION; INVASION; APATINIB;
D O I
10.1016/j.ejphar.2021.174214
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The transcription factor ETS-1 (E26 transformation specific sequence 1) is the key regulator for malignant tumor cell proliferation and invasion by mediating the transcription of the invasion/migration related factors, e.g. MMPs (matrix metalloproteinases). This work aims to identify the novel small molecule inhibitors of ETS-1 using a small molecule compound library and to study the inhibitors' antitumor activity against hepatocellular carcinoma (HCC). The luciferase reporter is used to examine the inhibition and activation of ETS-1's transcription factor activity in HCC cells, including a highly invasive HCC cell line, MHCC97-H, and five lines of patient-derived cells. The inhibition of the proliferation of HCC cells is examined using the MTT assay, while the invasion of HCC cells is examined using the transwell assay. The anti-tumor activity of the selected compound on HCC cells is also examined in a subcutaneous tumor model or intrahepatic tumor model in nude mice. The results show that for the first time, four compounds, EI1 similar to EI-4, can inhibit the transcription factor activation of ETS-1 and the proliferation or invasion of HCC cells. Among the four compounds, EI-4 has the best activation. The results from this paper contribute to expanding our understanding of ETS-1 and provide alternative, the safer and more effective, HCC molecular therapy strategies.
引用
收藏
页数:11
相关论文
共 41 条
[21]   miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway [J].
Shao, Qing-Ping ;
Wei, Chen ;
Yang, Jie ;
Zhang, Wen-Zhou .
ONCOTARGETS AND THERAPY, 2020, 13 :7213-7227
[22]   Cancer statistics, 2020 [J].
Siegel, Rebecca L. ;
Miller, Kimberly D. ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (01) :7-30
[23]   Quantitative examination of the inhibitory activation of molecular targeting agents in hepatocellular carcinoma patient-derived cell invasion via a novel in vivo tumor model [J].
Sun, Huiwei ;
Feng, Fan ;
Xie, Hui ;
Li, Xiaojuan ;
Jiang, Qiyu ;
Chai, Yantao ;
Wang, Zhijie ;
Yang, Ruichuang ;
Li, Ruisheng ;
Hou, Jun .
ANIMAL MODELS AND EXPERIMENTAL MEDICINE, 2019, 2 (04) :259-268
[24]   AKT inactivation causes persistent drug tolerance to EGFR inhibitors [J].
Tetsu, Osamu ;
Phuchareon, Janyaporn ;
Eisele, David W. ;
Hangauer, Matthew J. ;
McCormick, Frank .
PHARMACOLOGICAL RESEARCH, 2015, 102 :132-137
[25]  
WANG C, 2020, PHARMACOL RES, V161
[26]   The Global Burden of Liver Disease: The Major Impact of China [J].
Wang, Fu-Sheng ;
Fan, Jian-Gao ;
Zhang, Zheng ;
Gao, Bin ;
Wang, Hong-Yang .
HEPATOLOGY, 2014, 60 (06) :2099-2108
[27]   miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib [J].
Wang, Leisheng ;
En, He ;
Yang, Lei ;
Zhang, Yanbing ;
Sun, Baisheng ;
Gao, Jianjiang .
ONCOTARGETS AND THERAPY, 2019, 12 :6825-6838
[28]   A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway (Publication with Expression of Concern. See vol. 16, 2025) [J].
Wang, Shu ;
Zhang, Yingshi ;
Ren, Tianshu ;
Wu, Qiong ;
Lu, Hongyuan ;
Qin, Xiaochun ;
Liu, Yuyan ;
Ding, Huaiwei ;
Zhao, Qingchun .
CELL DEATH & DISEASE, 2020, 11 (06)
[29]   A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells [J].
Wang, Yanli ;
Tang, Zigui .
ONCOTARGETS AND THERAPY, 2018, 11 :8529-8541
[30]   Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo [J].
Wei, Ling ;
Lun, Yongzhi ;
Zhou, Xiaoping ;
He, Shang ;
Gao, Lijuan ;
Liu, Yan ;
He, Zheng ;
Li, Baoming ;
Wang, Chengbin .
PHARMACOLOGICAL RESEARCH, 2019, 143 :73-85